[Federal Register Volume 62, Number 26 (Friday, February 7, 1997)]
[Notices]
[Pages 5836-5837]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-3081]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Prospective Grant of Exclusive License: Vaccines for Dengue and 
Other Flaviviruses

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a limited field of use exclusive world-wide license to practice the 
invention embodied in U.S. Patent No. 5,494,671, issued February 27, 
1996 (U.S. Patent Application Serial No. 07/747,785, filed August 20, 
1991), entitled ``C-Terminally Truncated Dengue and Japanese 
Encephalitis Virus Envelope Proteins'' to Hawaii Biotechnology Group, 
Inc. of Aiea, Hawaii. The patent rights in this invention have been 
assigned to the United States of America.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be 
royalty-bearing and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be 
limited to the field of subunit vaccines against Dengue and Japanese 
Encephalitis produced in animal cells. This license will not include 
live virus, killed virus or DNA-based vaccines or the use of vaccinia 
virus as a vector, or immunogen. This prospective exclusive license may 
be granted unless within 60 days from the

[[Page 5837]]

date of this published notice, NIH receives written evidence and 
argument that establishes that the grant of the license would not be 
consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The patent describes the use of C-terminally truncated flavivirus 
envelope proteins in vaccines against flavivirus infections. The 
invention also relates to recombinant viruses which encode the 
truncated protein and to host cells infected therewith.

ADDRESSES: Requests for a copy of this issued patent, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to: Gloria H. Richmond, Patent Advisor, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-
7057 ext 268; Facsimile: (301) 402-0220; E-mail: Gloria 
<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="27754e444f4a48494367696e6f0960687109">[email protected]</a> Applications for a non-exclusive or exclusive license 
filed in a response to this notice will be treated as objections to the 
grant of the contemplated license. Only written comments and/or 
applications for a license which are received by NIH on or before April 
8, 1997 will be considered. Comments and objections submitted in 
response to this notice will not be made available for public 
inspection, and, to the extent permitted by law, will not be released 
under the Freedom of Information Act, 5 U.S.C. 552.

    Dated: January 28, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-3081 Filed 2-6-97; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>